{
    "organizations": [],
    "uuid": "9f71ce5db89297672a82ed8398f904745554d18d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-astrazeneca-says-fasenra-receives/brief-astrazeneca-says-fasenra-receives-eu-approval-idUSFWN1P50J5",
    "ord_in_thread": 0,
    "title": "BRIEF-Astrazeneca Says ‍Fasenra Receives EU Approval",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 10 (Reuters) - Astrazeneca Plc:\n* ‍FASENRA RECEIVES EU APPROVAL FOR SEVERE EOSINOPHILIC ASTHMA​\n* ASTRAZENECA - ‍FASENRA IS ALSO UNDER REGULATORY REVIEW IN JAPAN AND SEVERAL OTHER COUNTRIES, WITH EXPECTED REGULATORY DECISIONS IN H1 2018​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-01-10T23:14:00.000+02:00",
    "crawled": "2018-01-11T12:31:51.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "astrazeneca",
        "plc",
        "receives",
        "eu",
        "approval",
        "severe",
        "eosinophilic",
        "astrazeneca",
        "also",
        "regulatory",
        "review",
        "japan",
        "several",
        "country",
        "expected",
        "regulatory",
        "decision",
        "h1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}